The Presidencies’ perspective on the pharmaceutical strategy: Europe’s to-do list on access to medicines
EPHA #A2MDialogues
25 November 2020

16:00-17:00 CET

online
Our fourth dialogue in a series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.
Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.
Following the publication of the EU’s Pharmaceutical Strategy by the European Commission, senior representatives of the upcoming EU Presidencies (Portugal & Slovenia) and the Netherlands offer their perspective on what should be prioritised and debate next steps in European pharmaceutical policy.
Panelists

Rui Ivo Santos
President
INFARMED, Portugal

Momir Radulovic
Executive Director
Slovenian Medicines Agency

Marcel van Raaij
Director
Medicines & Medical Technologies
Dutch Ministry of Health
Moderated by

Yannis Natsis,
Policy Manager, Universal Access to Affordable Medicines
European Public Health Alliance
On social media
🎥 Following live the @EPHA_EU webinar #A2MDialogues welcoming the new #EUpharmaceuticalstrategy as a good starting point to create a future-proof and patient-centred pharmaceutical environment in Europe!
— European Alliance for Access to Safe Medicines (@EAASMeds) November 25, 2020
Read the new publication at https://t.co/97FQsyhMuI https://t.co/QsT03f0JhB
"We don't necessarily need to speed up the regulatory approval of drugs. As we already have tools to address specific cases that needs it." Says R. Ivo Santos from @INFARMED_IP , speaking about the #EUPharmaStrategy at #A2MDialogues
— Catta (@CattaFra) November 25, 2020
Hearing @MarcelvanRaaij , key leader in the access2medicines debate, welcoming and praising the #EUPharmaStrategy makes think that the @EU_Health is going to theh right direction. #A2MDialogues
— Catta (@CattaFra) November 25, 2020
Let's make sure that patient, consumer and public health organisations are involved in the implementation of the #EUPharmaStrategy. They have been ignored for the management of the #COVID19 pandemic which brought to inadequate decisions and push-back from EU citizens.
— Charlotte Roffiaen (@EU4Ublog) November 25, 2020
Council conclusions are to be expected under the Portuguese EU Presidency building on the #PharmaStrategy #A2MDialogues #MakeItHappen
— Devaliere Alienor (@AlieDevaliere) November 25, 2020
Invited by @EPHA_EU, I was happy to discuss the pharma strategy of the EC together with Momir Radulovic and Rui Ivo Santos @INFARMED_IP @AgencijaJAZMP. Thanks @YNatsis for leading the conversation. pic.twitter.com/tF0KXK0mGy
— Marcel van Raaij (@MarcelvanRaaij) November 25, 2020